HomeCompareIPNFF vs PFE

IPNFF vs PFE: Dividend Comparison 2026

IPNFF yields 22988.51% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPNFF wins by $209253913157569118208.00M in total portfolio value
10 years
IPNFF
IPNFF
● Live price
22988.51%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$209253913157569118208.00M
Annual income
$207,478,497,165,779,060,000,000,000.00
Full IPNFF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — IPNFF vs PFE

📍 IPNFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPNFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPNFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPNFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPNFF
Annual income on $10K today (after 15% tax)
$1,954,022.99/yr
After 10yr DRIP, annual income (after tax)
$176,356,722,590,912,200,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, IPNFF beats the other by $176,356,722,590,912,200,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPNFF + PFE for your $10,000?

IPNFF: 50%PFE: 50%
100% PFE50/50100% IPNFF
Portfolio after 10yr
$104626956578784559104.00M
Annual income
$103,739,248,582,889,530,000,000,000.00/yr
Blended yield
99.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IPNFF
No analyst data
Altman Z
-161.4
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPNFF buys
0
PFE buys
0
No recent congressional trades found for IPNFF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPNFFPFE
Forward yield22988.51%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$209253913157569118208.00M$51.1K
Annual income after 10y$207,478,497,165,779,060,000,000,000.00$27,210.54
Total dividends collected$209136897216972292096.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IPNFF vs PFE ($10,000, DRIP)

YearIPNFF PortfolioIPNFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,309,551$2,298,850.57$9,161$701.38+$2.30MIPNFF
2$498,668,571$496,197,351.96$8,610$859.79+$498.66MIPNFF
3$100,661,493,199$100,127,917,828.11$8,366$1,081.25+$100661.48MIPNFF
4$18,997,308,529,480$18,889,600,731,757.26$8,483$1,405.66+$18997308.52MIPNFF
5$3,352,041,078,501,299$3,331,713,958,374,754.50$9,084$1,907.24+$3352041078.49MIPNFF
6$553,002,537,294,905,860$549,415,853,340,909,500.00$10,418$2,732.78+$553002537294.90MIPNFF
7$85,301,813,974,046,130,000$84,710,101,259,140,560,000.00$13,007$4,193.56+$85301813974046.11MIPNFF
8$12,303,154,006,383,179,000,000$12,211,881,065,430,949,000,000.00$18,010$7,005.87+$12303154006383178.00MIPNFF
9$1,659,267,282,046,792,600,000,000$1,646,102,907,259,962,700,000,000.00$28,216$12,979.89+$1659267282046792704.00MIPNFF
10$209,253,913,157,569,130,000,000,000$207,478,497,165,779,060,000,000,000.00$51,081$27,210.54+$209253913157569118208.00MIPNFF

IPNFF vs PFE: Complete Analysis 2026

IPNFFStock

ImagineAR Inc. provides an augmented reality (AR) platform that enables businesses, sports teams, and organizations to create and implement their own AR campaigns with no programming or technology experience. Its products include ImagineAR Augmented Reality Platform that allows the choice of engagement by marker, location, and Web-based activation; ImagineAR.com, an AR-as-a-service platform for desktops; ImagineAR mobile app; ImagineAR SDK/API; ImagineAR White-Label Mobile App; ImagineAR Cloud, a centralized content management system, where AR is securely stored and managed; and WebAR services. The company serves the retail, sports/live events, advertising/promotions, e-sports, and fundraising industries. The company was formerly known as Imagination Park Technologies Inc. and changed its name to ImagineAR Inc. in April 2020. ImagineAR Inc. was incorporated in 2011 and is headquartered in Vancouver, Canada.

Full IPNFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IPNFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPNFF vs SCHDIPNFF vs JEPIIPNFF vs OIPNFF vs KOIPNFF vs MAINIPNFF vs JNJIPNFF vs MRKIPNFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.